This inventor holds 178 USPTO granted patents and 112 published patent applications, plus 8 CIPO patents and 31 EPO patents, primarily in Heterodimeric Antibodies (CPC class C07K2317-24). Top assignees: Xencor, Inc., Allergan, Inc., Genentech, Inc.. Active years: 2006-2026.
Inventors with similar research interests:
Location History:
- Monrovia, CA (US) (2017 - 2020)
- Pasadena, CA (US) (2006 - 2024)
Company Filing History:
177 out of 227 
3 out of 2,287 
1 out of 3,298 
Years Active: 2006-2026
Areas of Expertise:
Title: John Desjarlais: Pioneering Innovator in Biotechnology
Introduction:
In the bustling city of Pasadena, California, resides an ingenious inventor whose remarkable contributions have significantly influenced the field of biotechnology. John Desjarlais, an esteemed patent holder and scientific visionary, has left an indelible mark through his diligent work and groundbreaking patents. Let us dive into his latest patents, his notable career highlights, and his fruitful collaborations.
Latest Patents:
A testament to John Desjarlais' innovative prowess, his latest patents demonstrate his expertise in optimizing antibody variable regions and developing heterodimeric antibodies. The patent titled "Optimized Antibody Variable Regions" reveals his groundbreaking work in creating optimized anti-CD3 variable sequences, supporting various bispecific formats, including those that utilize single-chain variable fragment (scFv) components. These optimized sequences offer promising prospects for therapeutic applications. Furthermore, Desjarlais has explored nucleic acid encoding for the polypeptide, as well as pharmaceutical compositions and medical uses related to these optimized antibodies.
Another significant patent by Desjarlais is "Heterodimeric Antibodies that bind CD3 and Tumor Antigens," which introduces novel heterodimeric antibodies. These antibodies display immense potential in targeting tumor antigens, contributing to the advancement of cancer therapeutics. By harnessing his expertise in antibody engineering, Desjarlais has opened pathways to developing more effective treatments for cancer patients.
Career Highlights:
John Desjarlais has accumulated an impressive portfolio of 145 patents, testifying to his unwavering dedication and astute scientific acumen. Throughout his illustrious career, Desjarlais has made substantial contributions to the biotechnology industry.
Having worked at renowned companies such as Xencor, Inc. and Allergan, Inc., Desjarlais has solidified his position as a pioneer in the field. In these organizations, he has proven his mettle, consistently pushing the boundaries of scientific innovation and fostering a culture of excellence.
Collaborations:
In his pursuit of scientific breakthroughs, Desjarlais has collaborated with esteemed professionals in the field. Notably, he has worked alongside Matthew Bernett, a distinguished researcher who shares his passion for advancing biotechnology. Together, they have synergistically driven transformative discoveries, reinforcing their status as thought leaders in the industry.
Another valued collaboration in Desjarlais' career is with Sher Bahadur Karki, whose expertise complements the inventive spirit of Desjarlais. Their collaborative efforts have resulted in remarkable advancements, contributing to the expanding body of knowledge within the biotechnology landscape.
Conclusion:
John Desjarlais, an exemplary inventor and a respected figure in the field of biotechnology, continues to reshape the scientific landscape with his innovative patents. His optimized antibody variable regions and heterodimeric antibodies hold the promise of revolutionary treatments for a wide range of medical conditions, particularly cancer. Desjarlais' notable career highlights and fruitful collaborations further testify to his unwavering commitment to pushing the boundaries of scientific innovation. We eagerly anticipate the next groundbreaking invention from this brilliant mind, as he paves the way for a future defined by revolutionary biomedical advancements.